AOPEP and chronic kidney disease: After adjusting for age group, sex, APO e4 carrier status, BMI, current smoking status, type 2 diabetes mellitus, hypertension, and CKD, there was still evidence of a 76% increase in the likelihood of cognitive impairment from no atherosclerosis to monoVD or polyVD (Table 3).